Growth hormone deficiency epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 7: Line 7:
==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
*Sex
 
*The sex distribution of patients with idiopathic growth hormone deficiency is 73% male and 27% female. <sup>[[null 4], [null 5], [null 6]]</sup> Cuttler et al published results of a survey of pediatric endocrinologists that growth hormone treatment was 1.3 times more common in boys than in girls. <sup>[[null 10]]</sup>
==== Sex ====
*Age
*The sex distribution of patients with idiopathic growth hormone deficiency is 73% male and 27% female.   
*Diagnosis of growth hormone deficiency is made during 2 broad age peaks. The first age peak occurs at 5 years, a time when children begin school   The second age peak occurs in girls aged 10-13 years and boys aged 12-16 years. While congenital GHD and most cases of idiopathic GHD are thought to be present from birth, diagnosis is often delayed until the patient’s short stature is noticed in relation to their peers.   Race
*Cuttler et al published results of a survey of pediatric endocrinologists that growth hormone treatment was 1.3 times more common in boys than in girls.  
*There is no apparent racial difference in the incidence of GHD the National Cooperative Growth Study (NCGS) Genentech’s now closed large North American database, revealed that 85% of patients receiving GH treatment for idiopathic GHD were white, 6% were black, and 2% were Asian.  Gender
 
*Growth hormone deficiency affects males and females equally   However, given the greater concern for boys with short stature in most societies, diagnosis tends to favor males over females. 73% of patients with idiopathic GHD in the NCGS were male.  patients with GHD from organic causes such as tumors and radiation, in which no gender bias should be present, were still 62% male.
==== Age ====
*In the United States commencing in the mid-1960s through April of 1985, natural human growth hormone (nGH) was used to treat child-onset GHD. In 1985, the FDA approved the use of Protropin brand of recombinant human (biosynthetic) growth hormone (rhGH) (somatropin [rDNA origin], manufacturered by Genentech, to treat child-onset GHD. Since then, similar, but not identical brands, of rhGH have come to the marketplace. In 1996, rhGH was approved or use in GHD adults. In the last 15 years, it has been recognized that growth hormone deficiency (GHD) in the adult leads to increased morbidity (metabolic syndrome, osteoporosis, muscle wasting, impaired quality of life) and increased incidence of cardiovascular events, a main cause of the increased mortality observed in this population. Pituitary adenomas and their treatment (surgery, radiation) are the most common cause of GHD in adults. In the United States, it is estimated that the incidence of growth hormone deficiency in children is between 1 in 4,000 and 1 in 10,000. More than 50,000 adults in the United States are growth hormone deficient, and 6,000 new cases are reported each year, including GHD children who transition to GHD as an adult.
*Diagnosis of growth hormone deficiency is made during 2 broad age peaks; the first age peak occurs at 5 years, a time when children begin school. The second age peak occurs in girls aged 10-13 years and boys aged 12-16 years.  
*While congenital GHD and most cases of idiopathic GHD are thought to be present from birth, diagnosis is often delayed until the patient’s short stature is noticed in relation to their peers.
 
==== Race ====
*There is no apparent racial difference in the incidence of GHD.   
 
==== Gender ====
*Growth hormone deficiency affects males and females equally.
*However, due to societies that care a lot about males short stature than the females, seventy-three percent of patients with idiopathic GHD in were males
*Patients with GHD from organic causes such as tumors and radiation, in which no gender bias should be present, were still 62% male.


==References==
==References==

Revision as of 22:21, 14 August 2017

Growth hormone deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Growth hormone deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Growth hormone deficiency epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Growth hormone deficiency epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Growth hormone deficiency epidemiology and demographics

CDC on Growth hormone deficiency epidemiology and demographics

Growth hormone deficiency epidemiology and demographics in the news

Blogs on Growth hormone deficiency epidemiology and demographics

Directions to Hospitals Treating Growth hormone deficiency

Risk calculators and risk factors for Growth hormone deficiency epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Epidemiology and Demographics

Incidence

Sex

  • The sex distribution of patients with idiopathic growth hormone deficiency is 73% male and 27% female.
  • Cuttler et al published results of a survey of pediatric endocrinologists that growth hormone treatment was 1.3 times more common in boys than in girls.

Age

  • Diagnosis of growth hormone deficiency is made during 2 broad age peaks; the first age peak occurs at 5 years, a time when children begin school. The second age peak occurs in girls aged 10-13 years and boys aged 12-16 years.
  • While congenital GHD and most cases of idiopathic GHD are thought to be present from birth, diagnosis is often delayed until the patient’s short stature is noticed in relation to their peers.

Race

  • There is no apparent racial difference in the incidence of GHD.

Gender

  • Growth hormone deficiency affects males and females equally.
  • However, due to societies that care a lot about males short stature than the females, seventy-three percent of patients with idiopathic GHD in were males
  • Patients with GHD from organic causes such as tumors and radiation, in which no gender bias should be present, were still 62% male.

References

Template:WH Template:WS